Introduction {#S1}
============

Stroke is one of the leading causes of chronic disability and mortality, with 102 million disability-adjusted life years lost annually ([@B61]). The Global Burden of Disease, Injuries, and Risk Factors Study (GBD 2015) reported a shift from communicable diseases toward non-communicable diseases like cerebrovascular events. While the incidence of stroke is decreasing in the developed world, it has peaked in low- and middle-income countries like India due to demographic transition and rapid shifts in the socioeconomic milieu ([@B66]). The estimated adjusted prevalence rate of stroke is reported to have a range of 84--262/100,000 in rural and 334--424/100,000 in urban India ([@B73]; [@B43]).

The only neuroprotective agent developed for stroke in clinical use is recombinant tissue plasminogen activator (rtPA), which is employed for thrombolysis and has a therapeutic window of merely 3--4.5 h. There is thus a compelling need to develop therapeutic agents that extend beyond the first few hours after onset of stroke. This requires a paradigm shift to the usage of new strategies from neuroprotection to neuro-restoration that treat the injured or compromised brain tissue.

The majority of stroke survivors are left with some degree of disability, particularly upper limb dysfunction, despite several neurorehabilitation therapies. Physical therapy incorporating exercises, motor learning principles, motor cortex stimulation (using rTMS, TDCS), and assistive technologies aid the restoration of functional movements ([@B62]). The emergence of regenerative medicine has fueled interest across readers and clinicians to study its potential. Over the last decade, an enormous amount of work has been done exploring the potential of a variety of cells like adult stem cells, umbilical cord blood, and cells from adipose tissue and skin.

Pattern of Stroke Recovery {#S1.SS1}
--------------------------

The recovery after stroke has been explained as a rich cascade of events encompassing cellular, molecular, genetic, demographic, and behavioral components. Such factors have been proven as covariates in therapeutic trials of restorative agents with a sound neurobiological basis. Advances in functional neuroimaging and brain mapping methods have provided a valuable parallel system of data collection for stroke recovery in humans. The recovery in a stroke-affected individual will largely depend on the size of lesion, the internal milieu of the brain injury, and the age and comorbid status of the patient. In general, the first epoch encompasses the initial hours after a stroke, when rapid change occurs in blood flow, edema, pro-inflammatory mechanisms. A second epoch is related to spontaneous behavioral recovery, which begins a few days after stroke onset and lasts several weeks. During this epoch, the brain is galvanized to initiate repair, as endogenous repair-related events reaching peak levels, suggesting a golden period for initiating exogenous restorative therapies. A third epoch begins weeks to months after stroke, when spontaneous behavioral gains have generally reached a plateau, and this stable state is responsive to many restorative interventions ([@B61]).

Mechanisms of Action of Stem Cells in Neural Repair {#S1.SS2}
---------------------------------------------------

Stem cells have the capacity to differentiate into all types of cells. Exogenously administered cells appear to stimulate endogenous reparative processes and do not replace injured cerebral tissue. It was once thought that intravenously administered cells would home in on the injured site and replace the dead neurons, but the current ideology for the use of these cells holds that these cells release many trophic factors like VEGF, IGF, BDNF, and tissue growth factors that stimulate brain plasticity and recovery mechanisms. Upregulation of growth factors, prevention of ongoing cell death, and enhancement of synaptic connectivity between the host and graft are some of the common pathways through which intravenous stem cells work as "chaperones." Regarding the timing of transplantation, preclinical studies have shown that cell therapy increases functional recovery after acute, sub-acute, and chronic stroke ([@B10]), but few studies have compared different time windows, with differing results according to the model system and cell type studied. All of the possible modes of action of stem cells have been described in [Figure 1](#F1){ref-type="fig"}.

![Mechanisms of action of Mesenchymal Stem Cells in treating stroke.](fnins-14-00473-g001){#F1}

Translational Approach for the Development of Regenerative Medicine in Brain Stroke {#S2}
===================================================================================

The unique capacity of stem cells of self-renewal and differentiation has been exploited to devise cell-based therapy for various neurodegenerative diseases, including brain stroke. There have been several studies, which will be discussed in the upcoming paragraphs, that report the use of stem cells in the treatment of various diseases. These studies have used stem cells of various kinds, such as adult stem cells (mesenchymal stem cells and neural stem cells), embryonic stem cells, and the latest kind, induced pluripotent stem cells. Apart from using different types of stem cells, scientists have also reported distinctive modes of action to support their study outcomes. Besides these variable points, there are other considerations like the dosage of stem cells, mode of administration of stem cells, and whether or not booster doses are required, depending upon the magnitude of the disease. Various groups have attempted to answer these vital questions through their research.

Ischemic stroke causes severe damage to the brain cells by destroying the heterogeneous cell population and neuronal connections along with vascular systems. The regenerative potential of several types of stem cells like embryonic stem cells, neural stem cells, adult stem cells (Mesenchymal stem cells), and induced pluripotent stem cells have been assessed for treating stroke. The outcomes and observations in these studies are not consistent. Most of the studies have only commented on the homing, survival, proliferation, and differentiation of stem cells on the site and their limited neuro-restorative ability. Embryonic stem cells (ESCs) are pluripotent cells derived from the inner cell mass of the blastocyst. There have been a few studies where engraftment of murine ESCs in mouse models of ischemia has led to the restoration of behavioral deficits, synaptic connections, and damaged neurons ([@B66]; [@B73]; [@B43]). However, the use of ESCs in the clinical setting is argued against by many other groups due to their immunogenic nature and teratoma-forming tendency ([@B23]; [@B29]; [@B24]). Hence, scientists are now trying to establish the neuro-restorative ability of other stem cell types. Neural stem cells (NSCs) are theoretically the most appropriate cell candidates for neuro-restoration as they belong to the same tissue source and have a natural tendency to differentiate into neuronal cells. NSCs are multipotent cells that are generally found in the subgranular zone of the dentate gyrus of the hippocampus ([@B68]). Engraftment of NSCs has been reported to lead to the reformation of synaptic connections and improvement in the electrophysiological properties of mature neurons in the damaged brain ([@B48]; [@B49]; [@B16]; [@B45]). They do so by improving the extracellular microenvironment and hence encouraging neuronal circuit plasticity ([@B47]; [@B35]; [@B52]; [@B27]). NSCs restore neuronal functions as they secrete several neurotrophic factors like BDNF and VEGF, which help in maintaining the health, generation, proliferation, and survival of the neurons, along with the maintenance of ECM ([@B20]; [@B28]; [@B33]; [@B59]). VEGF specifically helps in angiogenesis and vascular restoration of the blood vessels damaged due to ischemia ([@B60]; [@B55]). CNTF, GDNF, NGF, and other such factors secreted by NSCs also play vital roles in the protection, maintenance, and proliferation of neural cells ([@B1]).

Another type of cells with amazing neuro-restorative potential and that have several other desirable properties, like being immunologically naive, easy to extract and maintain and expand *in vitro*, and not having associated ethical concerns, are mesenchymal stem cells (MSCs) ([@B4]; [@B70]; [@B54]). MSCs are multipotent stem cells that have their niche in body tissues like bone marrow, adipose tissue, umbilical cord, umbilical cord blood, dental pulp, etc ([@B70]; [@B58]; [@B54]). Extracting MSCs from these tissues is a very well-established and easy process and has been very widely used in various clinical trials ([@B44]; [@B58]). MSCs lead to neuro-restoration by one or more modes of action such as the release of paracrine factors, cell replacement, mitochondrial transfer, etc. MSCs also have an angiogenic effect. They have been reported to induce angiogenesis by the release of vascular endothelial growth factor (VEGF) ([@B37], [@B36]; [@B13]; [@B56]). The only issue to be considered for using bone marrow-derived MSCs is the surgical intervention to obtain the bone marrow. Adipose tissue-derived MSCs have proved to be equally effective in neuro-regeneration, with the added advantages of being easily accessible and more abundant ([@B77]; [@B42]; [@B58]). Adipose tissue-derived MSCs have been known to play a protective role through the release of extracellular vesicles. There are studies reporting the safety and efficacy of extracellular vesicles derived from adipose tissue-derived MSCs ([@B51]; [@B84]; [@B15]; [@B5]). However, more detailed studies are required to establish MSCs as therapeutic agents.

Another type of stem cell that has been explored for its translational value recently is the induced pluripotent stem cell (iPSC). There has been a boom in research into iPSCs after the groundbreaking discovery by [@B64]. iPSCs have the edge over other types of stem cells due to being non-immunogenic, easy to access, and non-interventional and not giving rise to ethical concerns. However, their generation is still an unresolved issue, as the reprogramming efficiency is still very low. Additionally, some studies have reported the formation of teratoma in the mouse brain, which implies that the tumorigenicity of iPSCs needs to be addressed and resolved before taking them into the clinical setting. iPSCs seem to be formidable stem cells for tissue regeneration ([@B26]; [@B22]).

Bioactive Constituents in Brain Stroke: Combination Therapy {#S2.SS1}
-----------------------------------------------------------

The use of complementary and alternative medicine along with stem cell therapy also plays an important role in the recovery of brain stroke patients. During the stroke episode, most of the pro-inflammatory cytokines are involved, and many polyphenol compounds extracted from different parts of medicinal plants have been shown to protect against cerebral ischemia in pre-clinical models. Glycrrhizin extracted from the licorice root, *Glycrrhiza glabra*, protected against the rat brain injury induced by stroke. Intraperitoneal administration of Glycrrhizin pre- and post-stroke helped inhibit the infarction by ameliorating the IFN-γ mediated T-cell activity, which was partially modulated by high mobility group box-1 ([@B76]). The use of intravenous administration of recombinant plasminogen tissue activator (rtPA) was approved half a decade ago, but the limitations to rtPA treatment include a narrow therapeutic window of 4.5 h post-stroke and a high risk for hemorrhagic transformations. MSC transplantation in brain stroke patients is an existing approach, but inflammation has sometimes been observed in MSCs due to oxygen glucose deprivation during treatment. One study showed that a nano-formulation of gelatin-coated polycaprolactone loaded with naringenin, a strong anti-inflammatory, protected the MSCs against oxygen glucose deprivation-induced inflammation and also reduced the levels of pro-inflammatory cytokines (TNF-α, IFN-γ, and IL-β) and of the anti-inflammatory biomarkers COX-2, iNOS, and MPO ([@B2]). The active compound Eugenol, isolated from *Acorus gramineus*, was tested in a cerebral ischemia perfusion rat model. Pre-treatment with Eugenol in the rat model showed that it was prompt in attenuating cerebral ischemic injury by inducing autophagy via the AMPK/mTOR/P70S6K signaling pathway. In another study, the neuroprotective effect of quercetin was demonstrated in mice, and the findings suggested that the quercetin helped reduce apoptosis in the focal cerebral ischemia rat brain and that the mechanism may be related to the activation of the PI3K/Akt signaling pathway ([@B78]). The intragastric administration of berberin and glycyrrhizin showed neuroprotective effects in mice subjected to transient middle cerebral artery occlusion. The co-administration of glycyrrhizin and berberin showed more potent suppression on the HMGB1/TLR4/NF-kB pathway in comparison to treatment with either alone. The results of the study suggested that the administration of these compounds protects the brain from ischemia-reperfusion injury and that the mechanism may rely on their anti-inflammatory effects and, moreover, also by suppressing the activation of the HMGB1/TLR4/NF-kB signaling pathway ([@B86]). Medicinal plants contain several important bioactive constituents that help in several modalities. Numerous pre-clinical studies have been performed using plant-derived products that help modulate the proliferation and differentiation of MSCs, as well as being useful in the field of biomaterials. Therefore, the new combination therapy of phytochemicals along with stem cell therapy may become a new perspective in stem cell-based neuro-regeneration.

Pre-Clinical Studies With Stem Cells in Brain Stroke {#S3}
====================================================

The experimental evidence of the benefits of stem cells in treating stroke has been provided over the course of several years ([@B1]; [@B39]). The usefulness of various types of stem cells has been proclaimed in various neurological diseases, along with their safety and efficacy at both pre-clinical and clinical levels. The pre-clinical validation of stem cells in treating stroke has been instrumental. Various study groups have validated the use of stem cells in terms of various parameters such as type of stem cells, number/dose of stem cells, mode of administration, homing and tracking of stem cells, and safety and efficacy of stem cells ([@B85]; [@B11]).

The most commonly used and most widely explored stem cells in the treatment of stroke are MSCs. Among the various tissue sources of MSCs, the most common and widely explored are bone marrow and adipose tissue, with bone marrow being the oldest of all ([@B3]; [@B75]; [@B80]; [@B84]). However, neural stem cells and bone marrow-derived mononuclear stem cells have also been explored ([@B63]; [@B18]; [@B65]). In most of the pre-clinical studies, autologous bone marrow-derived MSCs have been used ([@B82]; [@B30]; [@B46]; [@B6]; [@B72]) to investigate the various aspects of stem cell transplantation in stroke. Several other studies report the use of MSCs from other tissue sources, like adipose tissue, umbilical cord, placenta, etc ([@B77]; [@B83]; [@B74]). MSCs are characterized for transplantation based on surface marker profiling, which includes the presence of markers like CD29, CD44, CD73, CD90, and CD105 and the absence of CD34/45, CD14, and HLA class II. Other critical factors that need to be considered for pre-clinical studies are the number/dose of cells to be administered and the mode of administration. Transplantations of MSCs range from 1 × 10^6^ to 8 × 10^6^ cells and are accomplished through different modes, including intravenous, intranasal, and intra-arterial ([@B14]; [@B57]; [@B82]; [@B77]; [@B38]; [@B53]; [@B11]). While there is evidence that the transplanted MSCs have homed and differentiated into neurons, astrocytes, and oligodendrocytes upon administration through intravenous, intranasal, and intracerebral modes, there are doubts on the migration of MSCs in the brain by the intravenous mode ([@B19]). Also, there are mixed reports on whether the transplantation of coaxed and naive stem cells can achieve the desired outcome in terms of functional recovery, BBB function, increased angiogenesis and vasculogenesis, and tissue regeneration ([@B32]; [@B69]). More detailed studies need to be done to establish a definitive stem cell therapy regime for stroke.

Clinical Trials of Regenerative Medicine in Brain Stroke {#S4}
========================================================

Cerebrovascular strokes can cause morbidity and mortality and induce long-term disability that affects quality of life. Stroke is associated with neuroinflammation, which plays a key role in the pathophysiology of cerebrovascular accidents of different types. We performed a rigorous search of a database on clinical studies with stroke and found more than 56 clinical trials on the use of regenerative medicine (autologous or allogeneic) for cerebrovascular stroke. Most of them used mesenchymal stem cells, adipose tissue, bone marrow-derived cells, and spinal cord and umbilical cord cells. [Table 1](#T1){ref-type="table"} presents a few clinical trials involving stem cell therapy (autologous and allogeneic), giving their study design, dose, route of administration, and outcomes. Our experience with regenerative medicine in stroke emphasizes the safety and tolerance of cells, whereas efficacy still needs to be addressed. More recovery in clinical and functional patterns was observed in patients administered with autologous bone marrow-derived cells than in the group with physiotherapy alone. We also tried to elucidate correlations between functional MRI and outcome after stroke, with increased activation in premotor and primary motor areas (PM and SMA), and contralesional M1 over activation. Our present randomized controlled trial studying the paracrine effects of autologous mononuclear stem cells in interim showed increased VEGF and BDNF post-treatment in all stroke patients, suggesting endogenous recovery after restorative therapies like stem cells and a structured neuro-rehabilitation regime. To counter the progression of the cerebral vascular disease post-stroke and repair the damage induced in different regions of the brain, various clinical trials with different stem cells like mesenchymal stem cells, adipose tissue-derived stem cells, and bone marrow mononuclear stem cells are ongoing ([Table 1](#T1){ref-type="table"}) that investigate potential efficacy and safety, without the occurrence of any adverse or severely adverse events.

###### 

List of Clinical trials using Stem cells in treating stroke.

  **Country and year**   **Study design**                                                                                             **Sample size**                          **Stroke type**                    **Cells from**                               **Interventional type**                      **Route of administration**   **Dose**                                                                   **Time point from onset of infusion**      **Followup (Months)**   **Primary outcome indicator**          **References**
  ---------------------- ------------------------------------------------------------------------------------------------------------ ---------------------------------------- ---------------------------------- -------------------------------------------- -------------------------------------------- ----------------------------- -------------------------------------------------------------------------- ------------------------------------------ ----------------------- -------------------------------------- ----------------
  South Korea, 2010      Open-label, observer-blinded clinical trial                                                                  16/36                                    Acute                              Posterior iliac crest                        MSCs, Conventional Treatment                 Intravenous                   50 × 10^6^                                                                 7 days                                     60                      mRS                                    [@B34]
  Spain, 2012            Single-blind controlled clinical trial phase I/II                                                            10/10                                    Subacute                           Posterior superior iliac crest               BM-MNCs, Conventional Treatment              Intraarterial                 159 × 10^6^                                                                Mean 5--9 days post occurrence of stroke   6                       NIHSS, BI, mRS                         [@B41]
  India, 2012            Non-Randomized controlled clinical trial                                                                     12/12                                    Chronic                            Posterior superior iliac crest               BM-MNCs, Conventional Treatment              Intravenous                   50--60 × 10^6^                                                             3 months--2 years post-stroke              6                       FMA, BI                                [@B9]
  India, 2013                                                                                                                         20/20                                    Chronic                            Post superior iliac crest                    MNC + MSCs                                   Intravenous                   50--60 × 10^6^                                                             3 months--2 years post-stroke              6                       BI, FMA                                [@B8]
  China, 2013                                                                                                                         60/60                                    Chronic                            Umbilical cord                               UC-MSCs                                      Subarachnoid + Intravenous    100 × 10^6^                                                                1 month and 6 years post-stroke            3                       FMA                                    [@B25]
  India, 2014            Multicentric, phase II parallel group controlled clinical trial                                              60/60                                    Subacute                           Posterior iliac crest                        BMSCs                                        Intravenous infusion          280.5 × 10^6^                                                              7--30 days                                 6                       NIHSS, BI                              [@B50]
  China, 2014            Randomized, single-blind clinical trial                                                                      15/15                                    Chronic                            PBSCs                                        PBSCs                                        Stereotactic                  3--8 × 10^6^                                                               6 month--5 years                           12                      NIHSS, mRS                             [@B12]
  China, 2014                                                                                                                         50/50                                    Subacute                           Lianoning blood centers                      UC-MSCs, Conventional treatment              Subarachnoid                  100 × 10^6^                                                                14--30 days post-stroke                    3                       NIHSS,FMA                              [@B21]
  Spain, 2014            Phase IIa, Prospective, randomized, double-blind, placebo-controlled, single-center, pilot clinical trial.   20/20                                    Acute                              Adipose tissue                               Allogenic MSCs from adipose tissue           Intravenous administration    1 million/unit/kg. body weight                                             2 weeks post-stroke                        24                      mRS, NIHSS, MRI, Biochemical markers   [@B19]
  USA, 2018              Phase I, Open label                                                                                          10/10                                    Acute, cortical ischemic stroke    Allogenic Umbilical cord                     Umbilical cord blood infusion                Intravenous administration    3.34 × 10^6^                                                               3--9 days                                  12                      mRS                                    [@B31]
  USA, 2019              Phase I, Single arm-                                                                                         25/30                                    Acute                              Bone marrow harvest (autologous)             B-MNCs                                       Intravenous administration    10 million cells/kg b.wt                                                   1--3 days                                  24                      mRS, NIHSS                             [@B71]
  China, 2019            Cohort (Phase I)                                                                                             9                                        Hemiparesis from ischemic stroke   Cells derived from human fetal spinal cord   NSI-566, primary adherent neural stem cell   Intracerebral injection       Cohort A = 1.2 × 10^7^ Cohort B = 2.4 × 10^7^ Cohort C = 7.2 × 10^7^       Mean 494 days                              24                      CT, fMRI, PET, DTI                     [@B81]
  California, 2019       Phase I/II Preliminary safety and efficacy studies                                                           Phase I (*n* = 15) Phase II (*n* = 21)   Chronic                                                                         Allogeneic Ischemia tolerant MSCs            Intravenous transfusion       Phase I (0.5, 1.0, and 1.5 million/kg b.wt) Phase II 1.5 million/kg b.wt                                              12                      BI, ECG, CT-Scan.                      [@B40]

mRS, Modified Rankin Score; MRI, Magnetic resonance imaging; PET, Positron emission tomography; CT, Computed tomography; NIHSS, National Institute of Health Stroke scale; BI, Barthel Index.

An open-labeled observer-blind clinical trial was conducted to evaluate the long-term safety and efficacy of autologous MSCs. Post-transplantation with MSCs, clinical improvement in patients was observed in the MSC-treated patient group, which was associated with the serum level of stromal cell-derived factor-1 and the degree of involvement of the sub-ventricular region of the lateral ventricle. No serious adverse effects were observed during long-term follow up of patients. The occurrence of comorbidities was similar in comparison to the control group ([@B34]). In another single-blind controlled phase I/II trial, patients with middle cerebral artery stroke were enrolled in the study. Autologous bone marrow mononuclear cells (BM-MNCs) were injected 5--9 days post-stroke. A higher plasma β-nerve growth factor level was observed post-injection, and no adverse events were observed for 6 months apart from two patients in whom partial seizures were observed at 3 months of follow up. The study result suggested that intra-arterial administration of BM-MNCs is safe and feasible ([@B41]). A non-randomized observational controlled study with autologous bone marrow mononuclear cells in chronic ischemic stroke showed better efficacy and did not observe any adverse effects or neurological abnormalities during long-term follow up of patients ([@B9]). Intravenous administration of autologous BM-MSCs was also shown to have better safety in a randomized, phase II, multicentric trial group in patients with subacute ischemic stroke ([@B50]). On the basis of the findings of pre-clinical studies with peripheral blood stem cells (PBSCs), randomized single-blind controlled studies were conducted in patients with middle cerebral artery infarction. Patients were enrolled as per the inclusion criteria of the study and received subcutaneous G-CSF injection for 5 consecutive days prior to stereotaxic implantation of immune-sorted PBSCs. No adverse events were observed during the study procedure or the follow up of the study. Clinical outcomes of the PBSC-treated and control groups were observed in terms of changes in NIHSS, ESS, EMS, and mRS from baseline to 12 months. Moreover, this study also provided important evidence on the efficacy of PBSCs in improving stroke-related motor deficits, the reconstruction of injured CST, and the rebuilding of electrophysiology activity from the brain to the limbs ([@B12]). Intravenous administration of allogeneic mesenchymal stem cells from adipose tissue in a phase II randomized, double-blind, placebo controlled single-center pilot clinical trial in patients 2 weeks post-acute stroke showed better efficacy without the occurrence of adverse events. Moreover, the use of allogenic MSCs could be an alternative therapy for the treatment of stroke because it has been demonstrated that they lack class II HLA antigens ([@B19]). Another study ([@B8]) reported the paracrine mechanism of bone marrow-derived mononuclear cells in chronic ichemic stroke patients. CD34+ was counted in BM-MNCs for each and every patient. Intravenously administered BM-MNCs secrete glial cell-derived neurotrophic factor and BDNF, IGF-1, and VGEF, which may protect against the dysfunction of motor neurons. The trial results suggested that the administration of BM-MNCs is safe and feasible for stroke patients. In another phase I, open-label, prospective clinical trial, patients with acute ischemic stroke received a single i.v. infusion of allogeneic human umbilical cord blood cells within a window of 3--10 days. Post-UCB infusion, graft-vs.-host disease, infection, and hypersensitivity were analyzed at patient follow up visits at 3, 6, and 12 months. Adverse events and severe adverse events (AE/SAE) in the patients that were directly or indirectly related to the investigational treatment were reported ([@B31]).

A single-arm, phase I clinical trial study of autologous bone marrow mononuclear cells for acute ischemic stroke showed a promising new investigational modality that may help widen the therapeutic window for patients with ischemic stroke. AEs/SAEs were observed post-transplantation, some of which may have been associated with the intervention but others of which may not have ([@B71]). In another single-site phase I study, the feasibility and safety of NSI-566 primary adherent neural cells derived from a single human fetal spinal cord were observed. Three different doses were investigated in a cohort study of patients, and it was shown that the transplantation of human spinal cord-derived neural stem cells into the peri-infarct area of stable stroke patients is beneficial. The mechanism potentially behind it is that the stem cell-derived tissue is largely composed of interneurons and glial cells, and these promote regeneration and act as bridges between regenerating neuronal fibers ([@B81]). A phase I/II preliminary safety and efficacy study of allogenic MSCs in chronic stroke patients showed the dose tolerability to be 1.5 million/kg body weight in phase I and phase II study. The primary outcome of intravenous administration of allogenic MSCs in patients was measured for 1 year, and secondary outcomes were measured in terms of behavioral changes. AEs/SAEs were observed in 13 patients that were probably not related to the intervention, and two mild AEs related to the study intervention were observed, urinary tract infection and intravenous site irritation. However, other mechanisms have also been shown that involve cell replacement, immunomodulatory action, and endogenous repair of brain damage post-stroke. The stem cell therapy in cerebrovascular accident depends overall upon their differentiation, inflammation, and ability to repair of endogenous processes. This regenerative medicine has emerged as an important tool in modern neurology, with potential efficacy in neurodegenerative disorder ([@B67]; [@B79]). After extensive findings of pre-clinical research, the clinical trials have conducted with different stem cells in stroke, in which the AEs/SAEs observed during or post transplantation may be directly or indirectly related to the intervention. The studies suggest that there must be a further continuation of pre-clinical and clinical studies of regenerative medicine in stroke patients to further elucidate the safety, efficacy, and toxicity pre and posting transplantation and their capacity to deliver potent efficacious regenerative medicine for stroke patients. Further clinical trials of regenerative medicine in cerebrovascular stroke are complete, with more results awaited.

Future Prospects {#S4.SS1}
----------------

Regenerative medicine is looking increasingly more enticing as we capture more evidence from past and current clinical trials in stroke ([@B8], [@B7]). The neurophysiology describing stem cells and their concatenated mechanisms suggests that restoration of brain function may be a realistic goal. There are several cellular labeling techniques available, including simple incubation, use of transfection agents, magnetoelectroporation, and magnetosonoporation. MR tracking with SPIOs and nanoparticles in a MCAo occlusion model of stroke has proven flawless in tracking cells but still needs clinical validation ([@B17]). To make this research a therapeutic boon in stroke, certain questions still need answers, such as the optimal cell delivery route, the initial engraftment and distribution pattern of injected cells, and how effectively injected cells migrate toward the affected sites.

While stem cells have proven to be a great resource for treating stroke, there are still several obstacles to be conquered in the near future. A variety of stem cells with multiple parameters have been under trial for the treatment of stroke. Starting from the kinds of stem cells in use, there are pluripotent stem cells (ESCs and iPSCs), neural stem cells, and adult stem cells (MSCs from various tissues). There are ethical concerns associated with pluripotent stem cells. Additionally, NSCs have limitations in their *in vitro* expansion (in terms of the number of NSCs required to be transplanted). MSCs are capable of combating this concern. Another issue is immunological tolerance between the host body and transplanted stem cells. This issue can be resolved by using the patient's own cells to derive iPSCs of MSCs (as they are devoid of HLA class II). Besides these concerns, there are several other concerns, such as whether the efficiency of cell extraction, expansion, and differentiation is sufficient for transplantation, as well as the best mode of injection and optimal number of injections. While there are several challenges to bringing stem cell therapy in the mainstream of treatment for various diseases, stem cell therapy has been established for treating several degenerative and other kinds of diseases. In future, all these points of concern need to be addressed to make stem cell therapy an abiding treatment regime for stroke.
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